Korio is a technology company.
Korio is the RTSM platform for flexibility, quality and speed, backed by decades of expertise so you can be Ready for the Trials Ahead™.
Korio has raised $6.0M across 1 funding round.
Korio has raised $6.0M in total across 1 funding round.
Korio has raised $6.0M in total across 1 funding round.
Korio's investors include Andreessen Horowitz, BIP Capital, Moderne Ventures, Redpoint Ventures.
Korio is a technology company that builds a Randomization and Trial Supply Management (RTSM) software platform for the clinical trials industry.[1][2][3][5] Its product enables flexible management of trial randomization, supply logistics, and compliance, serving pharmaceutical sponsors, biotech firms, and clinical sites by solving pain points like slow mid-study adaptations, high costs, and poor support in legacy systems.[1][5] The platform cuts mid-study change times and costs by 50%, supports diverse trial designs across therapeutic areas, and has gained momentum through a Series A funding round in September 2024 led by BIP Ventures, with participation from Excelerate Health Ventures and Boston Millennia Partners, fueling global expansion and client services growth.[1][3]
Korio was founded in 2021 and is headquartered in Doylestown, Pennsylvania.[1] Drawing on decades of RTSM expertise from its team, the company emerged to address gaps in legacy systems that fail modern trial complexities, such as frequent protocol amendments affecting 76% of trials.[5] Early traction included powering complex trials like a personalized medicine oncology study and a rare disease trial for a small biotech, transitioning them from manual processes to automated, intuitive RTSM with responsive expert support.[6] A pivotal moment came with the 2024 Series A raise, validating its model and enabling scaled operations.[1]
Korio rides the trend of modernizing clinical trial operations amid rising complexity in study designs, personalized medicine, and global supply chains, where legacy RTSM systems cause delays and cost overruns.[1][5][6] Timing is ideal as trials increasingly demand agility—mid-study changes are now standard—and biotechs seek cost-effective tools over expensive incumbents.[1] Favorable market forces include post-pandemic acceleration in digital trial tech and investor interest in healthtech efficiency, as seen in Korio's funding from specialized VCs like BIP Ventures.[1][3] It influences the ecosystem by enabling faster trial execution for startups, reducing barriers for rare disease and oncology innovation, and promoting "mid-study rescue" migrations from outdated providers.[6]
Korio is positioned to capture share in the RTSM market by prioritizing adaptability and service in an industry ripe for disruption, with Series A funds accelerating global reach and features like mid-study migrations.[1][6] Upcoming trends like AI-driven trials and decentralized studies will favor its flexible platform, potentially expanding to integrated suites while maintaining specialist focus. Its influence may grow as more sponsors prioritize quality over vendor lock-in, evolving from niche innovator to standard for efficient, compliant trials—ready for the escalating demands ahead.[1][5]
Korio has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $6.0M Series A | Andreessen Horowitz, BIP Capital, Moderne Ventures, Redpoint Ventures |